Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have earned an average rating of “Hold” from the five brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $29.6667.

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $15.21 on Wednesday. Eton Pharmaceuticals has a 12-month low of $11.09 and a 12-month high of $23.00. The company has a market cap of $407.93 million, a PE ratio of -60.84 and a beta of 1.19. The stock has a 50 day simple moving average of $15.90 and a 200-day simple moving average of $17.05. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Anchor Capital Advisors LLC raised its stake in shares of Eton Pharmaceuticals by 10.6% in the fourth quarter. Anchor Capital Advisors LLC now owns 40,668 shares of the company’s stock valued at $688,000 after purchasing an additional 3,890 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Eton Pharmaceuticals by 3.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 196,263 shares of the company’s stock worth $3,319,000 after acquiring an additional 6,099 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Eton Pharmaceuticals by 20.7% in the fourth quarter. BNP Paribas Financial Markets now owns 277,458 shares of the company’s stock valued at $4,692,000 after buying an additional 47,668 shares in the last quarter. Intech Investment Management LLC increased its position in Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock valued at $210,000 after acquiring an additional 1,244 shares in the last quarter. Finally, Jefferies Financial Group Inc. increased its holdings in shares of Eton Pharmaceuticals by 33.8% in the fourth quarter. Jefferies Financial Group Inc. now owns 118,300 shares of the company’s stock valued at $2,000,000 after purchasing an additional 29,860 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.